Targeting APOC3 in the Familial Chylomicronemia Syndrome
Daniel Gaudet(Brigham and Women's Hospital), Joseph L. Witztum(University of California, San Diego), Rosanne M. Crooke(Ionis Pharmaceuticals (United States)), Richard S. Geary(Ionis Pharmaceuticals (United States)), Diane Brisson(Université de Montréal), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Veronica Alexander(Ionis Pharmaceuticals (United States)), W. S. Singleton(Ionis Pharmaceuticals (United States)), Karine Tremblay(Université de Montréal), Mark J. Graham(Ionis Pharmaceuticals (United States)), Brenda F. Baker(Ionis Pharmaceuticals (United States))
Cited by 492
Related Papers
Role of oxidized low density lipoprotein in atherogenesis.
|Journal of Clinical Investigation|1991|2.7k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
A comprehensive classification system for lipids
|Journal of Lipid Research|2005|1.8k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k